× × × × × × × × x 8 natera × × × Ⅹ Ｘ Ｘ Ｘ Ｘ Ｘ × × × × × × Ｘ Ｘ × × × Ⅹ Ｘ Ｘ Ｘ Ｘ Ｘ × × × × Ｘ Ｘ x × x × × × Ｘ Ｘ × × × × × × × x × × × × × × × × × × × × × × × × × Natera, Inc. Investor presentation × × × × × × × × × Third Quarter 2022 Earnings Call November 8, 2022 × × × × × X X × × × × × Safe harbor statement × × × × X X × × This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts cont ...

PART I — FINANCIAL INFORMATION [ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)](index=5&type=section&id=ITEM%201.%20FINANCIAL%20STATEMENTS%20(UNAUDITED)) This section presents Natera, Inc.'s unaudited condensed consolidated financial statements for the quarter ended September 30, 2022, including balance sheets, statements of operations and comprehensive loss, statements of stockholders' equity, and statements of cash flows, along with detailed notes on business description, significant accounting policies, revenue recognition, fair value measurements, financial instruments, balance sheet components, leases, commitments and contingencies, stock-based compensation, debt, income taxes, net loss per share, and subsequent events [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section provides a snapshot of Natera's financial position, detailing assets, liabilities, and stockholders' equity at specific points in time | Metric | September 30, 2022 (in thousands) | December 31, 2021 (in thousands) | | :--------------------------------- | :-------------------------------- | :-------------------------------- | | **Assets** | | | | Cash and cash equivalents | $57,042 | $84,386 | | Short-term investments | $464,112 | $829,896 | | Accounts receivable, net | $236,362 | $122,074 | | Total current assets | $829,629 | $1,093,138 | | Total assets | $1,009,112 | $1,236,487 | | **Liabilities** | | | | Total current liabilities | $267,281 | $218,956 | | Long-term debt financing | $281,336 | $280,394 | | Total liabilities | $647,491 | $583,183 | | **Stockholders' Equity** | | | | Accumulated deficit | $(1,800,062) | $(1,394,836) | | Total stockholders' equity | $361,621 | $653,304 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) This section outlines Natera's financial performance over specific periods, detailing revenues, expenses, and net loss | Metric | Three months ended Sep 30, 2022 (in thousands) | Three months ended Sep 30, 2021 (in thousands) | Nine months ended Sep 30, 2022 (in thousands) | Nine months ended Sep 30, 2021 (in thousands) | | :----------------------------------- | :--------------------------------------------- | :--------------------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Product revenues | $199,831 | $153,940 | $584,415 | $413,971 | | Licensing and other revenues | $10,806 | $4,176 | $18,555 | $38,487 | | Total revenues | $210,637 | $158,116 | $602,970 | $452,458 | | Cost of product revenues | $115,436 | $80,511 | $326,862 | $221,870 | | Research and development | $65,510 | $98,457 | $228,504 | $192,397 | | Selling, general and administrative | $147,667 | $128,485 | $444,769 | $364,273 | | Loss from operations | $(119,052) | $(150,197) | $(399,267) | $(328,508) | | Net loss | $(121,480) | $(151,273) | $(405,226) | $(331,152) | | Basic and diluted net loss per share | $(1.25) | $(1.63) | $(4.20) | $(3.72) | [Condensed Consolidated Statements of Stockholders' Equity](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) This section details changes in Natera's stockholders' equity, reflecting the impact of net losses, unrealized gains/losses, and equity transactions - Total stockholders' equity decreased from **$653.3 million** at **December 31, 2021**, to **$361.6 million** at **September 30, 2022**, primarily due to a net loss of **$405.2 million** and unrealized losses on available-for-sale securities of **$17.3 million**, partially offset by increases from stock-based compensation and common stock issuances[24](index=24&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section summarizes Natera's cash inflows and outflows from operating, investing, and financing activities over specific periods | Cash Flow Activity | Nine Months Ended Sep 30, 2022 (in thousands) | Nine Months Ended Sep 30, 2021 (in thousands) | | :----------------------------------- | :-------------------------------------------- | :-------------------------------------------- | | Cash used in operating activities | $(350,374) | $(236,500) | | Cash provided by (used in) investing activities | $308,421 | $(284,697) | | Cash provided by financing activities | $14,467 | $567,673 | | Net increase in cash, cash equivalents and restricted cash | $(27,486) | $46,476 | | Cash, cash equivalents and restricted cash, end of period | $57,128 | $95,331 | [Notes to Unaudited Interim Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Unaudited%20Interim%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and additional information supporting the unaudited interim condensed consolidated financial statements [1. Description of Business](index=10&type=section&id=1.%20Description%20of%20Business) This note describes Natera, Inc.'s core business as a diagnostics company leveraging cell-free DNA technology across women's health, oncology, and organ health markets - Natera, Inc. is a diagnostics company utilizing proprietary cell-free DNA (cfDNA) technology and bioinformatics for disease management[29](index=29&type=chunk)[30](index=30&type=chunk) - Initially focused on women's health (e.g., Panorama NIPT, Horizon Carrier Screening), the company has expanded into oncology (Signatera) and organ health (Prospera) markets[29](index=29&type=chunk)[30](index=30&type=chunk) - It operates CLIA-certified laboratories and offers a cloud-based distribution model, Constellation, for laboratory partners[29](index=29&type=chunk)[30](index=30&type=chunk) [2. Summary of Significant Accounting Policies](index=10&type=section&id=2.%20Summary%20of%20Significant%20Accounting%20Policies) This note outlines the key accounting principles and estimates used in preparing Natera's financial statements, including going concern considerations - The company's financial statements are prepared in conformity with U.S. GAAP for interim financial information, with no material changes to significant accounting policies during the nine months ended **September 30, 2022**[31](index=31&type=chunk)[32](index=32&type=chunk)[45](index=45&type=chunk) - Key estimates include allowance for doubtful accounts, average selling price from insurance payors, operating lease assets/liabilities, deferred revenues, stock-based compensation, and income tax uncertainties[31](index=31&type=chunk)[32](index=32&type=chunk)[45](index=45&type=chunk) - Natera has incurred net losses since inception, with a **$405.2 million** net loss for the nine months ended **September 30, 2022**, and an accumulated deficit of **$1.8 billion**[36](index=36&type=chunk)[38](index=38&type=chunk) - The company anticipates continued losses and negative operating cash flows, requiring additional equity or debt financing to fund operations and growth[36](index=36&type=chunk)[38](index=38&type=chunk) - The company believes its existing cash and marketable securities (**$57.1 million** cash, **$464.1 million** investments as of **September 30, 2022**) will be sufficient for at least **12 months** after **November 8, 2022**[36](index=36&type=chunk)[43](index=43&type=chunk) [3. Revenue Recognition](index=18&type=section&id=3.%20Revenue%20Recognition) This note details Natera's policies for recognizing revenue from product sales and licensing agreements, including variable consideration and disaggregation by payer and geography - Product revenues are primarily from prenatal genetic tests, oncology testing, and are recognized when test results are delivered[85](index=85&type=chunk)[87](index=87&type=chunk)[93](index=93&type=chunk)[95](index=95&type=chunk) - Licensing and other revenues come from the Constellation cloud-based platform and strategic

Natera, Inc. (NASDAQ:NTRA) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager, Oncology Conference Call Participants Tejas Savant - Morgan Stanley Dave Delahunt - Goldman Sachs Catherine Schulte - Baird Max Masucci - Cowen Puneet Souda - Leerink Julia Qin - JPMorgan Vidyun Bais - BTIG Connor Stevenson - Craig-Hallum Mason Carrico - Stephens Operator Welcome to Nat ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------|-------|-------|-------|-------|---------|-------|-------|-------|-------|-------------|-------| | | | | | | | | | | | | | | | | | | | × × | | × | | × × | × | × | | natera | | | | | × × | | × | | xxxxx | × | | | | | | | | × × | | × | | × × | × | | | | | | | | × × | | × | × | × | X X X | | | | | | | | × × × × | | × × | × × | × × | × × × x x x | | | | | | | | × × | | × | × | × | x | | | | | | | | × × | | × | × | × | x X ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 01-0894487 (State or Other ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------|-------|-------|-------|-------|-------|-------|-----------------|-------|-------|-------| | | | | | | | | | | | | | | | | | × | × | × | × × | | × | | | 8 natera | | | | × | | | X X X X X X | | | | | | | | | × | | | X X X X X X | | | | | | | | | × | | | x x x x | | × | | | | | | | × | | | × × × × | | × | | | | | | | × | | | X X X X X X X X | | | | | | | | | × | | | × × × × × × × × | | | | | | | | | × | | | × × × × × × × × | ...

Natera, Inc. (NASDAQ:NTRA) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager, Oncology Conference Call Participants Tejas Savant - Morgan Stanley Stephanie Yan - Cowen Catherine Schulte - Baird Matt Sykes - Goldman Sachs Puneet Souda - SVB Securities Operator Welcome to Natera???s 2022 First Quarter Financial Results Conference Call. At this time, all participants ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in Its Charter) 13011 McCallen Pass Building A Suit ...

Natera, Inc. (NASDAQ:NTRA) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager of Oncology & Transplant Conference Call Participants Tejas Savant - Morgan Stanley Puneet Souda - SVB Leerink Tycho Peterson - JPMorgan Catherine Schulte - Baird Max Masucci - Cowen & Company Mark Massaro - BTIG Dan Leonard - Wells Fargo Alex Nowak - Craig-Hallum Capital Group Kyle ...

8 natera × × × × × × × × × × × × × × × × × × Ⅹ Ｘ × × × × × × × × × × X X X X X X X × × Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ⅹ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Ｘ Natera, Inc. Investor presentation Fourth Quarter 2021 Earnings Call Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our pro ...